Earendil: A Blueprint for a Multipolar Life Sciences Era
The $787M financing points to a new global architecture in biotech
False
The $787M financing points to a new global architecture in biotech
False
False
August 20, 2026
6 min read
From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development
August 19, 2026
5 min read
Can iPSC platforms deliver consistent, commercial-scale cell therapies for large patient populations?
August 18, 2026
10 min read
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
August 14, 2026
4 min read
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
False
Affiliations:
Specialties:
Areas of Expertise:
4 Topic Commentaries
Earendil: A Blueprint for a Multipolar Life Sciences Era
Julio Frenk, MD, MPH, PhD
Global health policy and health systems
•Harvard University
Nalini Anand, JD, MPH
Global health policy and research administration
•Georgetown University
Andrew Forsyth, PhD
Global health research policy and analytics
•Fogarty International Center, National Institutes of Health
Cassidy R. Sugimoto, PhD
Science of science and science policy
•Georgia Institute of Technology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.